Pharsight

1. Boniva patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5662918	ROCHE	Pharmaceutical agents containing diphosphonic acids and salts thereof	Sep, 2014 (9 years ago)

Market Authorisation Date: 06 January, 2006

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/mL, 3 mL Vial	31 Aug, 2007	1		02 Sep, 2014	Extinguished
150 mg	16 May, 2007	8	19 Mar, 2012	06 May, 2023	Deferred
2.5 mg	16 May, 2007	1		06 May, 2023	Extinguished

Strength	Dosage	Availability
EQ 3MG BASE/3ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INTRAVENOUS	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6133418	ROCHE	Synthetic peptide inhibitors of HIV transmission	Nov, 2014 (9 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5464933	ROCHE	Synthetic peptide inhibitors of HIV transmission	Jun, 2013 (10 years ago)
US6475491	ROCHE	Treatment of HIV and other viral infections using combinatorial therapy	Jun, 2015 (8 years ago)

Market Authorisation Date: 13 March, 2003

Treatment: Treatment of hiv

Dosage: INJECTABLE;SUBCUTANEOUS

Strength	Dosage	Availability
90MG/VIAL	INJECTABLE;SUBCUTANEOUS	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5952340	ROCHE	Use of granisetron for the treatment of postoperative nausea and vomiting	Sep, 2016 (7 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-102)	Apr 29, 2014

Market Authorisation Date: 17 September, 2004

Treatment: Post operative nausea and vomiting

Dosage: INJECTABLE;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.1 mg/mL, 1 mL single dose vial	08 Mar, 2007	1
1 mg/mL, 1 mL vials	01 Jun, 2004	1	31 Dec, 2007	04 May, 2019	Eligible
1 mg/mL, 4 mL multi-dose vials	19 Jul, 2004	1	31 Dec, 2007	04 May, 2019	Eligible

Strength	Dosage	Availability
EQ 1MG BASE/ML (EQ 1MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued
EQ 4MG BASE/4ML (EQ 1MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued
EQ 3MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5952375	ROCHE	Compounds and methods for synthesis and therapy	Feb, 2015 (9 years ago)
US5866601	ROCHE	Carbocyclic compounds	Feb, 2016 (8 years ago)
US5763483	ROCHE	Carbocyclic compounds	Dec, 2016 (7 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5952375 (Pediatric)	ROCHE	Compounds and methods for synthesis and therapy	Aug, 2015 (8 years ago)
US5866601 (Pediatric)	ROCHE	Carbocyclic compounds	Aug, 2016 (7 years ago)
US5763483 (Pediatric)	ROCHE	Carbocyclic compounds	Jun, 2017 (6 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-251)	Aug 02, 2022
M(M-90)	Feb 22, 2013
New Patient Population(NPP)	Dec 21, 2015

Market Authorisation Date: 02 July, 2007

Treatment: Treatment of influenza

Dosage: CAPSULE;ORAL; FOR SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
30 mg and 45 mg	02 Aug, 2011	1	03 Aug, 2016	27 Dec, 2016	Eligible
75 mg	15 Nov, 2010	1	03 Aug, 2016	27 Dec, 2016	Eligible
6 mg/mL	18 Jun, 2015	1	20 Feb, 2018	27 Dec, 2016	Extinguished